Bariatric Surgery in the Era of Obesity Management Medication: A Paradigm Shift or a Complementary Tool?
Journal of Bariatric Surgery · 2024
DOI: 10.4103/jbs.jbs_17_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Bariatric Surgery, 2024. Verfasst von Randeep Wadhawan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Obesity, a multifaceted and chronic disease, has escalated to epidemic proportions worldwide. According to the World Health Organization,[1] over 2.5 billion adults were classified as overweight in 2022, of whom more than 890 million were obese. This prevalence has nearly tripled since 1975, with projections indicating that over 1 billion individuals will live with obesity by 2030. Obesity is a major risk factor for numerous comorbidities, including type 2 diabetes mellitus, hypertension, cardiovascular disease, obstructive sleep apnea, osteoarthritis, and certain malignancies. Moreover, the economic burden is staggering, with obesity-related healthcare costs estimated at $2.0 trillion annually, nearly 2.8% of global GDP.[2] Bariatric and metabolic surgery (BMS) has long been considered the most effective intervention for achieving significant and sustained weight loss, along with profound metabolic benefits. A meta-analysis published in Surg Endoscopy[3] reports mean excess weight loss (EWL) of 53% for sleeve gastrectomy (SG) and 63% for Roux-en-Y gastric bypass (RYGB) over 5 years, while a long-term study by Hatami etal.[4] found a remarkable 77.6% EWL following one-anastomosis gastric bypass (OAGB). The Swedish Obese Subjects trial[5] demonstrated sustained weight loss over two decades and a 23% reduction in all-cause mortality for patients undergoing surgery compared to nonsurgical controls. BMS is also a powerful tool for improving glucose homeostasis. Diabetes remission rates reach 78% for RYGB and 62% for SG, according to a meta-analysis of 136 studies.[6] OAGB shows even greater promise, with nearly 89% diabetes remission at 5 years in a systematic review by Balasubaramaniam and Pouwels[7] A study published in The Lancet[8] highlighted that 50% of surgical patients maintained glycemic control without medications after 5 years, underscoring the metabolic benefits of BMS that extend beyond weight loss. Despite these advantages, bariatric surgery is not without challenges. Postoperative complications, such as bleeding, leaks, and infections, occur in 5%–10% of cases, while long-term issues such as nutritional deficiencies and hernias are also observed. In addition, BMS requires significant upfront costs, although it is cost-effective in the long run due to reduced healthcare expenditures. Recent advancements in pharmacotherapy, particularly with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide, have transformed the landscape of obesity management. These medications enhance satiety, reduce appetite, and slow gastric emptying, offering a noninvasive alternative to surgery. The efficacy of GLP-1 RAs has been well-documented. The STEP trials[9] showed that semaglutide 2.4 mg weekly led to an average weight loss of 14.9% over 68 weeks, nearly double that achieved with lifestyle modifications alone. Similarly, the SURMOUNT-1 trial[10] revealed unprecedented weight loss of up to 22.5% with tirzepatide, with 57% of participants achieving at least 20% weight loss – results that approach the efficacy of some surgical interventions. However, Obesity Management medications (OMMs) have limitations. Weight regain upon discontinuation is a common concern, emphasizing the need for ongoing treatment. Gastrointestinal side effects, including nausea, vomiting, and diarrhea, are frequent, while severe adverse events such as pancreatitis, gastroparesis, and thyroid cancer though rare, warrant consideration. In addition, the high annual cost of OMMs, often exceeding $13,000 per patient, poses significant barriers to accessibility, particularly in low-resource settings. While OMMs provide a less invasive option, BMS remains superior in terms of total weight loss and remission of obesity-related conditions. BMS offers additional benefits independent of weight loss,[11] such as alterations in gut hormones (e.g., ghrelin and GLP-1) and bile acid signaling, mechanisms not entirely replicated by pharmacotherapy. Furthermore, the sustainability of outcomes is a critical distinction; while BMS demonstrates durability over decades,[12] pharmacotherapy often requires lifelong administration to maintain weight loss, increasing the risk of nonadherence and weight regain. From an economic perspective, the upfront costs of surgery are offset by long-term healthcare savings, whereas the recurring expenses of OMMs create an ongoing financial burden, particularly for uninsured patients. Emerging evidence supports the integration of BMS and OMMs as complementary tools. A 2023 study published in obesity surgery[11] found that GLP-1 RAs effectively manage suboptimal weight loss or weight regain following surgery,[13] achieving an additional 5%–10% weight reduction. A study by Cunningham etal.[14] demonstrated that in patients with a body mass index (BMI) >60 kg/m2, the use of preoperative pharmacotherapy significantly optimized surgical outcomes by promoting weight loss and minimizing perioperative risks. In conclusion, the choice between BMS and pharmacotherapy should be individualized based on patient-specific factors such as BMI, comorbidities, and treatment preferences. While OMMs offer a viable option for individuals with lower BMI (25–30 kg/m2) or those ineligible for surgery, BMS remains the cornerstone for patients with severe obesity (BMI >35 kg/m2) or refractory T2DM. BMS and OMMs are not competitors but complementary components of a comprehensive obesity management strategy. By integrating these modalities, guided by multidisciplinary care and personalized treatment plans, we can optimize outcomes in the fight against obesity – a global health challenge demanding a multifaceted approach.
Zitieren
APA
Wadhawan, R. (2024). Bariatric Surgery in the Era of Obesity Management Medication: A Paradigm Shift or a Complementary Tool?. Journal of Bariatric Surgery. https://doi.org/10.4103/jbs.jbs_17_24
Vancouver
Wadhawan R. Bariatric Surgery in the Era of Obesity Management Medication: A Paradigm Shift or a Complementary Tool?. Journal of Bariatric Surgery. 2024. doi:10.4103/jbs.jbs_17_24
BibTeX
@article{Wadhawan2024,
author = {Wadhawan, Randeep},
title = {Bariatric Surgery in the Era of Obesity Management Medication: A Paradigm Shift or a Complementary Tool?},
journal = {Journal of Bariatric Surgery},
year = {2024},
doi = {10.4103/jbs.jbs_17_24}
}
EUVIMED